shutterstock_1120355471-zimmytws

zimmytws / Shutterstock.com

31 July 2019AmericasSarah Morgan

IPR of pre-AIA patents isn’t unconstitutional, finds Fed Circuit

In a defeat for biotech company Celgene, the US Court of Appeals for the Federal Circuit has concluded that the retroactive application of inter partes review (IPR) proceedings to a pre-American Invents Act (AIA) patent isn’t unconstitutional.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

PTAB grants IPR of Celgene patents after Kyle Bass challenge

28 October 2015 The Coalition for Affordable Drugs, an organisation closely tied to hedge fund manager Kyle Bass, has persuaded the Patent Trial and Appeal Board to institute an inter partes review concerning the validity of two patents owned by biopharmaceutical company Celgene.

USPTO rejects Celgene bid for Bass sanctions

28 September 2015 The US Patent and Trademark Office has rejected a request by biopharmaceutical company Celgene to sanction hedge fund manager Kyle Bass and his organisation the Coalition for Affordable Drugs.

More on this story

PTAB grants IPR of Celgene patents after Kyle Bass challenge

28 October 2015 The Coalition for Affordable Drugs, an organisation closely tied to hedge fund manager Kyle Bass, has persuaded the Patent Trial and Appeal Board to institute an inter partes review concerning the validity of two patents owned by biopharmaceutical company Celgene.

USPTO rejects Celgene bid for Bass sanctions

28 September 2015 The US Patent and Trademark Office has rejected a request by biopharmaceutical company Celgene to sanction hedge fund manager Kyle Bass and his organisation the Coalition for Affordable Drugs.

More on this story

PTAB grants IPR of Celgene patents after Kyle Bass challenge

28 October 2015 The Coalition for Affordable Drugs, an organisation closely tied to hedge fund manager Kyle Bass, has persuaded the Patent Trial and Appeal Board to institute an inter partes review concerning the validity of two patents owned by biopharmaceutical company Celgene.

USPTO rejects Celgene bid for Bass sanctions

28 September 2015 The US Patent and Trademark Office has rejected a request by biopharmaceutical company Celgene to sanction hedge fund manager Kyle Bass and his organisation the Coalition for Affordable Drugs.

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB